Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BIOVF NASDAQ:BNTX NASDAQ:INSM NASDAQ:RPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOVFSwedish Orphan Biovitrum$29.18$29.66$25.80▼$32.25$10.39B0.4536 shsN/ABNTXBioNTech$96.74-7.3%$108.79$81.20▼$131.49$25.08B1.39874,805 shs5.15 million shsINSMInsmed$145.93+0.1%$119.40$60.40▼$149.08$30.82B0.972.21 million shs1.93 million shsRPRXRoyalty Pharma$36.36-0.9%$36.36$24.05▼$38.00$21.40B0.583.74 million shs3.65 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOVFSwedish Orphan Biovitrum0.00%0.00%+0.72%-8.79%-6.71%BNTXBioNTech-7.26%-13.98%-14.22%-9.22%-2.55%INSMInsmed+0.10%+0.57%+18.77%+47.81%+100.56%RPRXRoyalty Pharma-0.93%+0.80%-0.27%+4.36%+30.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOVFSwedish Orphan Biovitrum$29.18$29.66$25.80▼$32.25$10.39B0.4536 shsN/ABNTXBioNTech$96.74-7.3%$108.79$81.20▼$131.49$25.08B1.39874,805 shs5.15 million shsINSMInsmed$145.93+0.1%$119.40$60.40▼$149.08$30.82B0.972.21 million shs1.93 million shsRPRXRoyalty Pharma$36.36-0.9%$36.36$24.05▼$38.00$21.40B0.583.74 million shs3.65 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOVFSwedish Orphan Biovitrum0.00%0.00%+0.72%-8.79%-6.71%BNTXBioNTech-7.26%-13.98%-14.22%-9.22%-2.55%INSMInsmed+0.10%+0.57%+18.77%+47.81%+100.56%RPRXRoyalty Pharma-0.93%+0.80%-0.27%+4.36%+30.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOVFSwedish Orphan Biovitrum 4.00Strong BuyN/AN/ABNTXBioNTech 2.76Moderate Buy$135.8040.38% UpsideINSMInsmed 2.94Moderate Buy$139.86-4.16% DownsideRPRXRoyalty Pharma 3.33Buy$48.0032.01% UpsideCurrent Analyst Ratings BreakdownLatest BIOVF, INSM, BNTX, and RPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$136.009/8/2025INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $172.009/3/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $171.008/21/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$126.00 ➝ $144.008/20/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$111.00 ➝ $135.008/20/2025INSMInsmedWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform8/14/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$138.00 ➝ $136.008/14/2025INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$126.00 ➝ $139.008/14/2025INSMInsmedStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$121.00 ➝ $145.008/13/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$114.00 ➝ $142.008/13/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$126.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOVFSwedish Orphan Biovitrum$2.46B4.22$2.05 per share14.22$10.71 per share2.72BNTXBioNTech$2.88B8.08N/AN/A$87.61 per share1.10INSMInsmed$363.71M84.81N/AN/A$1.60 per share91.21RPRXRoyalty Pharma$2.31B9.20$4.16 per share8.75$17.56 per share2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOVFSwedish Orphan Biovitrum$367.52M$1.1924.52∞N/A16.05%11.67%6.34%10/23/2025 (Estimated)BNTXBioNTech-$719.92M-$1.60N/AN/AN/A-12.20%-1.84%-1.59%11/3/2025 (Estimated)INSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)RPRXRoyalty Pharma$858.98M$1.7321.027.482.2944.23%25.54%14.11%11/5/2025 (Estimated)Latest BIOVF, INSM, BNTX, and RPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million8/6/2025Q2 2025RPRXRoyalty Pharma$1.10$1.14+$0.04$0.05$750.06 million$578.67 million8/4/2025Q2 2025BNTXBioNTech-$1.41-$1.60-$0.19-$1.82$161.26 million$306.46 million7/16/2025Q2 2025BIOVFSwedish Orphan Biovitrum$0.18$0.24+$0.06$0.19$644.68 million$649.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIOVFSwedish Orphan BiovitrumN/AN/AN/AN/AN/ABNTXBioNTech$1.531.58%N/AN/A N/AINSMInsmedN/AN/AN/AN/AN/ARPRXRoyalty Pharma$0.882.42%N/A50.87%5 YearsLatest BIOVF, INSM, BNTX, and RPRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/18/2025RPRXRoyalty Pharmaquarterly$0.222.48%8/15/20258/15/20259/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOVFSwedish Orphan Biovitrum0.221.000.66BNTXBioNTech0.018.618.48INSMInsmed0.456.686.33RPRXRoyalty Pharma0.741.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOVFSwedish Orphan BiovitrumN/ABNTXBioNTech15.52%INSMInsmedN/ARPRXRoyalty Pharma54.35%Insider OwnershipCompanyInsider OwnershipBIOVFSwedish Orphan BiovitrumN/ABNTXBioNTech19.20%INSMInsmed3.00%RPRXRoyalty Pharma18.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOVFSwedish Orphan Biovitrum1,937356.00 millionN/ANot OptionableBNTXBioNTech6,772240.40 million194.24 millionOptionableINSMInsmed1,271211.38 million205.03 millionOptionableRPRXRoyalty Pharma80583.17 million472.95 millionOptionableBIOVF, INSM, BNTX, and RPRX HeadlinesRecent News About These CompaniesEmpowered Funds LLC Makes New $8.01 Million Investment in Royalty Pharma PLC $RPRXSeptember 13 at 4:36 AM | marketbeat.comRoyalty Pharma: Investor Day UpsideSeptember 12 at 4:08 PM | seekingalpha.comPetrus Trust Company LTA Makes New $227,000 Investment in Royalty Pharma PLC $RPRXSeptember 12 at 4:32 AM | marketbeat.comEP Wealth Advisors LLC Takes $242,000 Position in Royalty Pharma PLC $RPRXSeptember 12 at 3:32 AM | marketbeat.comRoyalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)September 11 at 9:03 PM | seekingalpha.comRoyalty Pharma Plc (RPRX) Investor Day 2025 TranscriptSeptember 11 at 8:16 PM | seekingalpha.comRoyalty Pharma ‘on track’ to deliver portfolio receipts of $4.7B by 2030September 11 at 7:12 PM | msn.comRoyalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab ProgramSeptember 11 at 7:12 PM | finance.yahoo.comRoyalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value CreationSeptember 11 at 7:12 PM | markets.businessinsider.comRoyalty Pharma plc (RPRX) Analyst/Investor Day - SlideshowSeptember 11 at 10:04 AM | seekingalpha.comRoyalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value CreationSeptember 11 at 7:00 AM | globenewswire.comUSS Investment Management Ltd Decreases Stock Holdings in Royalty Pharma PLC $RPRXSeptember 11 at 4:26 AM | marketbeat.comRoyalty Pharma Scores Relative Strength Rating Upgrade; Hits Key ThresholdSeptember 10 at 3:31 PM | msn.comRoyalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty MarketSeptember 10 at 8:42 AM | markets.businessinsider.comRoyalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty MarketSeptember 10 at 7:30 AM | globenewswire.comRoyalty Pharma PLC $RPRX Shares Acquired by Uniplan Investment Counsel Inc.September 10 at 5:43 AM | marketbeat.comAlliancebernstein L.P. Acquires 86,873 Shares of Royalty Pharma PLC $RPRXSeptember 10 at 3:53 AM | marketbeat.com1 Mid-Cap Stock with Exciting Potential and 2 Facing ChallengesSeptember 9, 2025 | finance.yahoo.comRoyalty Pharma Plc (RPRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comAmundi Sells 1,316,620 Shares of Royalty Pharma PLC $RPRXSeptember 9, 2025 | marketbeat.comBaird Financial Group Inc. Has $1.59 Million Position in Royalty Pharma PLC $RPRXSeptember 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOVF, INSM, BNTX, and RPRX Company DescriptionsSwedish Orphan Biovitrum OTCMKTS:BIOVF$29.18 0.00 (0.00%) As of 09/12/2025Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.BioNTech NASDAQ:BNTX$96.74 -7.57 (-7.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$96.62 -0.11 (-0.12%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$145.93 +0.14 (+0.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$145.25 -0.68 (-0.47%) As of 09/12/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Royalty Pharma NASDAQ:RPRX$36.36 -0.34 (-0.93%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$36.80 +0.44 (+1.21%) As of 09/12/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
